FIRST SAFETY ANALYSIS OF HPC AND HPE AS NEOADJUVANT THERAPY IN BREAST CANCER PATIENTS WITH HER2+

首页> 外文期刊>The Breast : >FIRST SAFETY ANALYSIS OF HPC AND HPE AS NEOADJUVANT THERAPY IN BREAST CANCER PATIENTS WITH HER2+

【24h】

FIRST SAFETY ANALYSIS OF HPC AND HPE AS NEOADJUVANT THERAPY IN BREAST CANCER PATIENTS WITH HER2+

机译：作为HER2 +乳腺癌患者新辅助治疗的HPC和HPE的第一安全性分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Breast :》 |2013年第1期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类胸部外科学;
关键词

相似文献

外文文献
中文文献
专利

1. FIRST SAFETY ANALYSIS OF HPC AND HPE AS NEOADJUVANT THERAPY IN BREAST CANCER PATIENTS WITH HER2+ [J] . The Breast : . 2013,第Suppla1期

机译：作为HER2 +乳腺癌患者新辅助治疗的HPC和HPE的第一安全性分析
2. Increased derived neutrophil-to-lymphocyte ratio and Breast Imaging-Reporting and Data System classification predict poor survival in patients with non-distant metastatic HER2+ breast cancer treated with neoadjuvant chemotherapy [J] . Yuyong Li, Yi Shao, Lishan Bai, Cancer Management and Research . 2018,第2016期

机译：衍生的中性粒细胞与淋巴细胞比例的增加以及乳房成像报告和数据系统的分类预测，使用新辅助化疗治疗的非远距离转移性HER2 +乳腺癌患者的生存率较低
3. Increased derived neutrophil-to-lymphocyte ratio and Breast Imaging-Reporting and Data System classification predict poor survival in patients with non-distant metastatic HER2+ breast cancer treated with neoadjuvant chemotherapy [J] . Yuyong Li, Yi Shao, Lishan Bai, Cancer Management and Research . 2018,第2013期

机译：衍生的中性粒细胞与淋巴细胞比例的增加以及乳房成像报告和数据系统的分类预测，使用新辅助化疗治疗的非远距离转移性HER2 +乳腺癌患者的生存率较低
4. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
5. Coregistration of serial breast MR studies for augmenting neoadjuvant chemotherapy response evaluation in breast cancer patients. [D] . Chittineni, Ruparani. 2008

机译：增强乳腺癌患者新系列辅助化疗反应评估的系列乳房MR研究的核心。
6. Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data [O] . Tamara Díaz-Redondo, Rocio Lavado-Valenzuela, Begoña Jimenez, 2019

机译：不同的病理完全应对率根据PAM50亚型在HER2 +乳腺癌患者中用Neoadjuvant Pertuzumab / rrastuzumab与曲妥珠单抗加标准化疗：现实世界数据分析
7. Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spaincost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spain [O] . R Colomer, E Ciruelos, J De la Haba, 2016

机译：西班牙治疗腹膜康氏症患者腹膜癌患者腹膜癌，胸瘤和多西紫杉醇患者腹膜癌患者的新辅助化疗的成本实用性分析

FIRST SAFETY ANALYSIS OF HPC AND HPE AS NEOADJUVANT THERAPY IN BREAST CANCER PATIENTS WITH HER2+

著录项

相似文献

相关主题

期刊订阅